Athens – September 26, 2016 – Finvent S.A., a high-performance niche software solutions provider for the Investment Management Industry, participated for the fourth time, in Greece Race for the Cure®, held in Athens, on Sunday 25 September 2016.
Greece Race for the Cure®, which is approved by the International Organization “Susan G. Komen for the Cure®”, is a charity event aimed at sponsoring the Greek Society of Women with Breast Cancer. Funds raised at the event will go toward breast cancer research and cure. The goal is to provide information to every woman in Greece about early detection methods and about the right steps that have to be taken – depending on the age – in order to be safe, according to international medical guidelines.
“It is very important for everyone to help so that the cure to cancer can be found.” said Mr. Makis Ioannou, Finvent CEO. “Promoting philanthropy and solidarity in the workplace is something Finvent holds to its core values. Corporate Responsibility is a concrete part of our mission, and offers employees from across the organization an outstanding opportunity to showcase their commitment to make a positive difference in our community.”
Finvent S.A., founded on 2001 as the exclusive distributor of SS&C Advent and a certified SS&C Advent Software outsourced partner, provides best-of-breed applications and professional services to all types of asset management firms, bank private & wealth management divisions, mutual funds and hedge funds, fund administrators and family offices, organizations based in South Eastern Europe, Italy, Malta, Iberia, Middle-East and Africa.
With operations in Cyprus, Greece and Spain and clients in over 13 countries in the region, Finvent is a leading provider of trusted software applications and related full range of pre-implementation and post-implementation services, which are designed to provide quick return-on-investment to money managers.
Finvent is a silver ISV partner to Microsoft and is an ISO 9001-2000 certified company.
Finvent Marketing Department
+30 210 33 17 374